Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
Cryoport announced that its IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support its clinical KIR-CAR T cell therapy programs. The agreement covers SynKIR-110 and SynKIR-310, which are currently in Phase 1 trials for solid tumors and lymphomas, respectively.
Key figures
- Drug Name
- SynKIR-110, SynKIR-310
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.